About this source
- Kind
- Regulatory or official document
- Primary or secondary
- primary
- Peer review
- unknown
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
US FDA compounding categorisation. Not a UK regulatory position and not a marketing-authorisation decision. Page content current as of 22 April 2026. Only some peptides on the page are in Category 2 (for example ipamorelin and kisspeptin-10); others appear in a table of nominations that were withdrawn.
Cited in
FDA compounding category status
BPC-157 · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.